glp-1 for alcohol use disorder medications get at the heart of addiction: study – WashU Medicine Association between GLP-1 RAs exposure

Results showed that among people without diabetes, GLP-1 drug use rose from 0.1% of the population in 2018 to 0.4% in 2022

Due to the unique anatomical relationship between the CNS and the nasal cavity, relatively quick along with easy access for nanodrugs to the brain could be realized via intranasal administration

Here is everything we know so far

This review included data from the European Medicines Agency (EMA) and Federal Drug Administration (FDA) including product information, the Netherlands Pharmacovigilance Centre and the Teratology Information Service of Switzerland

El-Tookhy OS, Shamaa AA, Shehab GG, et al